Helping patients reclaim a life of possibility
The Israel Amyloidosis Association held its annual conference on 23 October 2026, bringing together approximately 200 patients, clinicians and researchers from across Israel. The event took place just ahead of International Amyloidosis Day on 26 October and featured presentations from leading Israeli experts in haematology, cardiology and neurology. Alongside a series of lectures and panel…
Myeloma Patients Europe (MPE) will host a webinar the “ International Symposium on Amyloidosis (ISA 2026) highlights”, on Wednesday, 25 November 2026 at 17:00 CET. During this webinar, you will learn about the latest research findings in AL amyloidosis presented at ISA 2026, held from 14 to 18 November 2026 in Montevideo, Uruguay and organised…
Recently, AMEN Association, one of Myeloma Patients Europe’s (MPE) member organisations in Israel, carried out its “Changing Direction” campaign to help people living with myeloma and their families better understand the advanced treatment options available today and feel more confident when participating in treatment decisions alongside their healthcare team. The campaign was delivered in two…
On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together with pomalidomide, for myeloma patients who have received at least one previous line of treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible…
World Amyloidosis Day is 26 October. To mark the day, MPE is asking everyone in our community to download the MPE Amyloidosis Diagnosis Pathway and share it with their GP or family doctor. By helping primary care professionals recognise the signs and symptoms of AL amyloidosis earlier, we can play an important role in reducing…
September proved to be an extraordinary month for myeloma advocacy across MPE’s member network. Our members delivered bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month (BCAM) and European Myeloma Day (EMD) on 27 September.
Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after treatment. To inform myeloma patients and the myeloma…
Last week MPE was in Zagreb for the Autumn EORTC Quality of Life Group meeting, connecting with colleagues working to strengthen the role of quality-of-life data in cancer research. The EORTC is the European Organisation for Research and Treatment of Cancer, a cancer research organisation that brings people together to answer important questions about which…